NLR‐containing inflammasomes: Central mediators of host defense and inflammation
暂无分享,去创建一个
[1] G. Núñez,et al. Inflammasomes as microbial sensors , 2010, European journal of immunology.
[2] G. Cook,et al. The NLRP3 inflammasome, a target for therapy in diverse disease states , 2010, European journal of immunology.
[3] M. Saleh,et al. Genetics of inflammasome‐associated disorders: A lesson in the guiding principals of inflammasome function , 2010, European journal of immunology.
[4] E. Lavelle,et al. The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants , 2010, European journal of immunology.
[5] M. Lamkanfi,et al. NOD‐like receptor (NLR) signaling beyond the inflammasome , 2010, European journal of immunology.
[6] V. Hornung,et al. Critical functions of priming and lysosomal damage for NLRP3 activation , 2010, European journal of immunology.
[7] Guangxun Meng,et al. New insights into the nature of autoinflammatory diseases from mice with Nlrp3 mutations , 2010, European journal of immunology.
[8] L. Zitvogel,et al. Pyroptosis – a cell death modality of its kind? , 2010, European journal of immunology.
[9] F. Martinon. Signaling by ROS drives inflammasome activation , 2010, European journal of immunology.
[10] C. Dinarello,et al. IL‐1: Discoveries, controversies and future directions , 2010, European journal of immunology.
[11] P. Ricciardi-Castagnoli,et al. The controversial relationship between NLRP3, alum, danger signals and the next‐generation adjuvants , 2010, European journal of immunology.
[12] F. Sutterwala,et al. Sterile inflammatory responses mediated by the NLRP3 inflammasome , 2010, European journal of immunology.
[13] J. Tschopp,et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation , 2010, Nature Immunology.
[14] Kate Schroder,et al. The NLRP3 Inflammasome: A Sensor for Metabolic Danger? , 2010, Science.
[15] G. Dharmadhikari,et al. Interleukin-1 beta targeted therapy for type 2 diabetes , 2009, Expert opinion on biological therapy.
[16] E. Alnemri,et al. Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression1 , 2009, The Journal of Immunology.
[17] Fuping Zhang,et al. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. , 2009, Immunity.
[18] A. Vaag,et al. Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes , 2009, Diabetes Care.
[19] K. Fitzgerald,et al. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. , 2009, Cell host & microbe.
[20] C. Dinarello,et al. Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.
[21] G. Superti-Furga,et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome , 2009, Nature Immunology.
[22] Jasmyn A. Dunn,et al. HIN-200 Proteins Regulate Caspase Activation in Response to Foreign Cytoplasmic DNA , 2009, Science.
[23] Daniel R. Caffrey,et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1 activating inflammasome with ASC , 2009, Nature.
[24] E. Alnemri,et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA , 2009, Nature.
[25] H. Hammad,et al. Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome , 2008, The Journal of Immunology.
[26] K. Rock,et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.
[27] G. Núñez,et al. The Nlrp3 inflammasome is critical for aluminium hydroxide‐mediated IL‐1β secretion but dispensable for adjuvant activity , 2008, European journal of immunology.
[28] K. Moore,et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β , 2008, Nature Immunology.
[29] F. Re,et al. Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP31 , 2008, The Journal of Immunology.
[30] Richard A. Flavell,et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants , 2008, Nature.
[31] Allan Vaag,et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.
[32] J. Tschopp,et al. A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.
[33] W. Dietrich,et al. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin , 2006, Nature Genetics.
[34] F. Martinon,et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.
[35] J. Bertin,et al. PYPAF7, a Novel PYRIN-containing Apaf1-like Protein That Regulates Activation of NF-κB and Caspase-1-dependent Cytokine Processing* , 2002, The Journal of Biological Chemistry.
[36] F. Martinon,et al. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. , 2002, Molecular cell.
[37] S. Srinivasula,et al. Identification of Ipaf, a Human Caspase-1-activating Protein Related to Apaf-1* , 2001, The Journal of Biological Chemistry.
[38] C. Dinarello,et al. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. , 1998, International reviews of immunology.